Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Semaglutide
FDA-approved GLP-1 agonist for diabetes and obesity.
Plain-Language Label Highlights
Brand names: Ozempic, Wegovy, Rybelsus
Type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).
A weekly injection (or daily pill) that mimics a gut hormone, lowering blood sugar, slowing digestion, and reducing appetite.
May cause thyroid C-cell tumors in rodents — do not use if you or family have medullary thyroid cancer or MEN 2.
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
- •Stomach pain
- •Pancreatitis
- •Gallbladder disease
- •Kidney injury from dehydration
- •Diabetic eye disease progression
- •Low blood sugar (with insulin/sulfonylureas)
- •Personal/family history of medullary thyroid cancer
- •Multiple Endocrine Neoplasia type 2
- •History of pancreatitis (caution)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Mechanism of Action
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.
Research Areas
Common Research Protocols
Stepwise dose escalation to manage GI tolerability in approved indications.
Protocols summarized for educational reference from published research. Not dosing guidance.
Cited Research
Semaglutide for weight loss in adults with overweight or obesity (STEP 1)
Mean ~15% weight loss at 68 weeks versus placebo.
Cardiovascular outcomes with semaglutide (SELECT)
Reduced MACE in adults with CVD and overweight/obesity.
Important Considerations
- •FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- •Requires physician oversight and prescription.
- •Compounded versions vary in quality.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.